AR and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions: Therefore, the combination of the AR inhibitor MDV3100 and the UCHL1 inhibitor 6RK73 was effective in delaying the progression of Xp11.2 tRCC, especially PRCC‐TFE3 tRCC.